Global Disruption of Cell Cycle Progression and Nutrient Response by the Antifungal Agent Amiodarone* [S]

Yong-Qiang Zhang and Rajini Rao

From the Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

The antiarrhythmic drug amiodarone has fungicidal activity against a broad range of fungi. In Saccharomyces cerevisiae, it elicits an immediate influx of Ca$^{2+}$ followed by mitochondrial fragmentation and eventual cell death. To dissect the mechanism of its toxicity, we assessed the transcriptional response of S. cerevisiae to amiodarone by DNA microarray. Consistent with the drug-induced calcium burst, more than half of the differentially transcribed genes were induced by high levels of CaCl$_2$. Amiodarone also caused rapid nuclear accumulation of the calcineurin-regulated Crz1. The majority of genes induced by amiodarone within 10 min were involved in utilization of alternative carbon and nitrogen sources and in mobilizing energy reserves. The similarity to nutrient starvation responses seen in stationary phase cells, rapamycin treatment, and late stages of shift to diauxic conditions and nitrogen depletion suggests that amiodarone may interfere with nutrient sensing and regulatory networks. Transcription of a set of nutrient-responsive genes was affected by amiodarone but not CaCl$_2$, indicating that activation of the starvation response was independent of Ca$^{2+}$. Genes down-regulated by amiodarone were involved in all stages of cell cycle control. A moderate dose of amiodarone temporarily delayed cell cycle progression at G$_1$, S, and G$_2$/M phases, with the Swe1-mediated delay in G$_2$/M phase being most prominent in a calcineurin-dependent manner. Overall, the transcriptional responses to amiodarone revealed by this study were found to be distinct from other classes of antifungals, including theazole drugs, pointing toward a novel target pathway in combating fungal pathogenesis.

Fungal infections are a persistent problem, especially in immunocompromised patients undergoing treatment for AIDS, cancer, cystic fibrosis, and other diseases. Existing antifungal drugs have limitations in that there are relatively few classes with distinct mode of action; of these, the widely prescribed azole drugs are fungistatic and depend upon a healthy immune system for fungal clearance. The need for new drugs that combat resistance and improve the efficacy of existing antifungals is pressing. Amiodarone has been approved to treat ventricular arrhythmias since 1985. Pharmacological studies have shown its property as a cation channel blocker although it has multiple targets and a complex mechanism. Recent in vitro research in unicellular organisms demonstrated its microbial activity against a broad range of fungal species (1), bacteria (2), and protozoa (3). In Saccharomyces cerevisiae, it elicits an immediate Ca$^{2+}$ burst (4, 5) and subsequently a mitochondrial-mediated cell death program (6). Similarly, 12.5 µM amiodarone elevated cytosolic Ca$^{2+}$ in Trypanosoma cruzi but not in the host Vero cells (3). Low levels of amiodarone (1–4 µM), within the therapeutic range achieved in patients, were reported to exhibit synergistic fungicidal effects with azole drugs against pathogenic species of fungi (Candida and Cryptococcus) and protozoa (Trypanosoma), suggesting that the drug may be useful as a sensitizing agent in antimicrobial therapy (5).

A comprehensive view of the impact of amiodarone on microbial cellular pathways is prerequisite for its potential in vivo use as antifungal adjunct, and to understand mechanisms of drug toxicity and resistance. Phenotypic profiling of the set of S. cerevisiae single gene deletions for amiodarone hypersensitivity revealed the importance of genes involved in membrane trafficking and transport pathways, protein fate, and interaction with the cellular environment (5, 7). Extending the analysis to include additional drugs (tunicamycin, sulfometuron methyl, wortmannin) and ion (Ca$^{2+}$, Mn$^{2+}$) stress revealed that the major cellular components responsive to drug toxicity and ion stress localize to the endomembrane system. Notably, disruption of calcium and proton homeostasis by deletion of PMR1 (Golgi Ca$^{2+}$, Mn$^{2+}$-ATPase) and VMA (endomembrane/vacuolar H$^{+}$-ATPase) genes led to multidrug hypersensitivity. Genes involved in ergosterol biogenesis (ERG6, ERG24), lipid flipping and remodeling (SAC1, LEM3, CDC50, OPI1), and compartmental trafficking (RJC1, COG6, VPS20) were important for growth tolerance to toxic drugs. Together, these represented the first line of defense against diverse forms of toxic stress.

Phenotypic profiling of multidrug sensitivity also pointed to a significant transcriptional response: genes involved in chaperonin (HAP4, SNF5, SNF6, SWI3), histone modification (HFI1, GCN5), and transcription activation (SLT2, SRB8, SIN4, HCM1, SIP3, SFP1, UGA3) were important for survival in amiodarone (7). To gain a global perspective on the impact of this drug on gene expression networks, we profiled the genome-wide transcriptional response of S. cerevisiae to amiodarone by DNA microarray. Our findings demonstrate a prominent overlap between amiodarone and calcium stress responses, consistent with the drug-induced Ca$^{2+}$ burst reported earlier. Unexpectedly, transcriptional profiling

* This work was supported by a United States Public Health Service, National Institutes of Health NIAID Grant R01AI065983. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1–S3.

To whom correspondence should be addressed. Tel: 410-955-4732; Fax: 410-955-0461; E-mail: rao@jhmi.edu.
revealed that amiodarone appeared to disrupt nutrient sensing and regulatory networks and delay cell cycle progression. In addition to Ca$^{2+}$ stress, both cell cycle block and nutrient starvation may contribute to the antifungal mechanism of amiodarone.

**EXPERIMENTAL PROCEDURES**

**Yeast Strains, Media, and Amiodarone Treatment Conditions**—Yeast deletion mutants (swe1Δ, cnb1Δ, crz1Δ), isogenic to BY4742, were from the MATa S. cerevisiae deletion library (Invitrogen). Yeast strains were grown in standard synthetic complete medium or YPD medium at 30 °C. Liquid cultures were incubated at 30 °C with shaking (250 rpm) and growth was determined by absorbance at 600 nm. Amiodarone (Sigma) was added from a stock solution of 50 mM in dimethyl sulfoxide to 100-ml log phase culture (OD 0.1, synthetic complete medium) to concentrations specified in the figure legends. Me2SO was added to 0.03% (v/v) in the control culture. Two independent samples for each treatment (determined after reading A$_{600}$) were spread on YPD plates, incubated at 30 °C for 36 h before counting 500–1500 colonies to calculate cell viability.

Microarray Hybridization and Bioinformatic Analysis—S. cerevisiae BY4742 strain was used for DNA microarray experiment. Culture and amiodarone treatment conditions are as described above. The Me$_2$SO control samples were collected 10 min after Me$_2$SO addition. The amiodarone-treated samples were collected 10 min and 6 h after amiodarone addition. Cells were spun down at 4000 rpm and flash-frozen after removing the supernatant. Two independent samples for each treatment (Me$_2$SO control and amiodarone, 10 min and 6 h exposure) were collected and analyzed with DNA microarray. Total RNA was isolated by the hot acidic phenol extraction method as previously described (8). RNA concentration and purity were determined spectrophotometrically by measuring absorbance at 260 and 280 nm. The integrity of the RNA samples was confirmed by polyacrylamide gel electrophoresis. cDNA synthesis, labeling and hybridization, image scanning, and processing were conducted at the Johns Hopkins Microarray Core Facility. Briefly, first and second strand cDNA was synthesized with SuperScript II (Invitrogen) and DNA polymerase I (Invitrogen). Biotin-labeled cRNA was synthesized with T7 RNA Polymerase (ENZO Life Sciences, Inc.) and fragmented. Sample mixture was hybridized to Yeast Genome 2.0 Arrays (Affymetrix). The arrays were stained and washed using the Affymetrix GeneChip Fluidics Station 450 and Mini_euk2V3_450 fluids script. All arrays were scanned in the Affymetrix GeneChip Scanner 3000 and raw analysis performed with Affymetrix GeneChip Operating System (GCOS) 1.4. Subsequently microarray data were imported to GeneSpring 7.0 (Agilent Technologies) for normalization and analysis. Data for genes showing 2-fold or greater response to amiodarone were imported to Gene Cluster 3.0 (9) for hierarchical and k-means clustering analyses, along with previously published DNA microarray data for these genes in response to CaCl$_2$ (10), rapamycin (11), amino acid or nitro-

gen depletion, growth in YPD (12), diauxic shift (13), and four classes of antifungals (caspofungin, ketoconazole, 5-fluorocytosine, and amphotericin B14), downloaded from the publisher’s website or requested from the authors. Results were displayed with Java Tree View software and edited in Adobe Photoshop (Adobe Systems Inc.). Geneset enrichment analyses were performed on the server at the Munich Information center for Protein Sequences (MIPS) data base (mips.gsf.de/proj/functatDB/search_main_frame.html).

Quantitative RT-PCR—Aliquots of the same RNA samples used for DNA microarray were saved for quantitative RT-PCR. The RNA samples were treated with DNase I (Roche Diagnostics) to remove residual genomic DNA. First strand cDNA was synthesized from 1 μg of total RNA with SuperScript III Reverse Transcriptase (Invitrogen) according to the manufacturer’s instructions. Quantitative RT-PCR was conducted with SYBR Green PCR Master Mix in a 7500 Real Time PCR system (Applied Biosystems, Foster City, CA). A dissociation curve was generated at the end of each PCR to verify that a single DNA species was amplified. ACT1 was amplified as the reference gene to calculate -fold change for genes of interest. All quantitative RT-PCR experiments were conducted in triplicate. Data were analyzed with Sequence Detection Software (Applied Biosystems). -Fold changes and standard deviations were calculated with the standard curve method according to the manufacturer’s instructions.

**Fluorescence Microscopy**—For microscopy with FUN-1 (Invitrogen), BY4742 cells were exposed to amiodarone (15 μM) or Me$_2$SO for 10 min or 6 h, collected by centrifugation, and resuspended in 50 μl of synthetic complete medium with 4 μM FUN-1 dye (diluted from a stock of 200 μM in dimethyl sulfoxide). Following incubation at 30 °C for 1 h, cells were examined under a Zeiss Axiophot fluorescence microscope equipped with a Photometrics CoolSnap fx camera. The fluorescent dye was excited by UV light. Conversion of FUN-1 into cylindrical intravacuolar structures was monitored by recording fluorescent micrographs at emission wavelengths of 645 nm (metabolically active and inactive cells) or 525 nm (metabolically inactive cells only). To monitor Crz1p translocation, crz1Δ yeast cells expressing GFP-Crz1 from plasmid pKK249 (15) were grown to OD 0.1 and treated with CaCl$_2$ (50 mM) or amiodarone (15 μM) for specified time. Cells were collected by rapid centrifugation and visualized with the Zeiss Axioshot fluorescence microscope at emission wavelength of 525 nm. A total of 300–500 cells were counted for each condition to calculate percentage of cells showing nuclear translocation of Crz1p. Nuclei were stained with 1 μg/ml 4’,6-diamidino-2-phenylindole (Roche Diagnostics). Pseudo-colorization was done with Adobe Photoshop.

Flow Cytometry and Cell Cycle Manipulations—In experiments with asynchronous cultures, amiodarone (15 μM) and FK506 (1 μg/ml) were added to 200 ml of BY4742 yeast (OD 0.1) in YPD and samples collected at the specified time intervals. For cell cycle synchronization, 0.2 M hydroxyurea was used to arrest the yeast strains at S phase. The cells were then

2 The abbreviation used is: RT-PCR, reverse transcriptase-PCR.
Transcriptional Profiling of Amiodarone Response in Yeast

released into YPD medium for 15 min or 1 h before addition of amiodarone (15 μM). For flow cytometry, cultures were spun down, resuspended in 0.3 ml of 0.2 M Tris-HCl (pH 7.5) buffer, and fixed by addition of 0.7 ml of ethanol (95%) at 4°C for 2 h. The cells were washed with the above buffer once before treatment with RNase A solution (1 mg/ml in 0.2 M Tris-HCl buffer, pH 7.5) for 2 h at 37°C. The cells were washed once and stained with 1 μM SYTOX Green (Invitrogen) in 50 mM Tris-HCl (pH 7.5). Samples (20,000 cells) were analyzed with a FACScan instrument (BD Biosciences). Results were visualized with Flowjo software (Tree Star, Inc., Ashland, OR) and edited with Adobe Photoshop. Distribution of cell population in G1, S, and G2/M phases was calculated with Flowjo.

RESULTS

Dose-dependent Growth Inhibition and Metabolic Arrest by Amiodarone—To reveal a substantive transcriptional response to amiodarone without eliciting secondary effects, we sought a drug concentration that would prolong the doubling time of the culture by 2-fold. Fig. 1A shows that addition of amiodarone to an exponentially growing yeast culture in synthetic complete medium caused a dose-dependent inhibition of growth, with a doubling time of 110 min in the absence of drug increasing progressively to 150 (9 μM), 170 (12 μM), 230 (15 μM), and 380 min (18 μM). Additional amiodarone completely inhibited growth. At 15 μM, amiodarone was moderately fungicidal, with a 19 ± 2% decrease in colony forming units after a 10-min exposure to drug. Longer exposure times increased the fungicidal effect, with a loss in colony forming units of 34 ± 8% after 6 h. Similar effects were seen in cells loaded with the FUN-1 dye (16), which monitors loss of metabolic activity by a change in fluorescence from red cylindrical structures to diffuse green-yellow stain (Fig. 1B). Based on these results, we chose to monitor both early (10 min) and late (6 h) transcriptional response to a moderate dose of amiodarone (15 μM).

Overview of Differentially Transcribed Genes—Within 10 min of exposure to 15 μM amiodarone, we observed differential transcription of 352 genes, using a 2-fold margin as cut-off. Of these, 218 gene transcripts increased, whereas 134 decreased (supplemental data Table 1S). At 6 h, the response was considerably muted, with 106 genes maintaining a ≥2-fold increase and only 9 genes remaining at ≥2-fold decrease. These data suggest that the transcriptional response reached its peak shortly after drug exposure and diminished over time, consistent with the fungicidal efficacy of the drug. Because this was confirmed using additional time intervals (not shown), we focused our analysis on the transcriptional response at 10 min of drug exposure.

Relative to the yeast proteome, the differentially up-regulated gene products were significantly enriched in functional categories of metabolism (p value, 5.66 x 10^{-6}) and energy production (p value, 4.56 x 10^{-9}), with protein localization predominantly in membranes (plasma membrane and endomembranes) and in peroxisomes, as shown in Fig. 2. In contrast, down-regulated genes were highly enriched in functional categories of cell cycle and DNA processing (p value, 1.19 x 10^{-7}), cell type differentiation (p value, 1.60 x 10^{-5}), and cell communication (p value, 2.49 x 10^{-9}). Protein localization of down-regulated gene products showed significant enrichment in the yeast bud and cell periphery, whereas other cell compartments were represented at levels similar to the yeast proteome (Fig. 2).

To validate our DNA microarray data, we performed real time quantitative PCR on 26 genes representing a variety of enriched functional categories. Results from real time PCR were in good agreement with DNA microarray results (supplemental data Table 2S), with -fold change in transcript levels being similar to, or greater than results from microarray. This indicated that the DNA microarray results faithfully represented the transcriptional response to amiodarone.

FIGURE 1. Growth and metabolic effects of amiodarone. Amiodarone was added to log phase (OD 0.1) cultures of yeast in synthetic complete medium at the indicated concentrations. Control cultures contained Me2SO (0.03% v/v). A, cell growth was monitored by measuring absorbance at 600 nm in cultures incubated at 30°C for 6 h. B, cells were stained with 4 μM FUN-1 to examine metabolic activity as described under “Experimental Procedures.” Cells showing cylindrical spindle-shaped structures (red) are metabolically active, whereas cells showing diffuse stains (red and green) are metabolically inactive.
Amiodarone Triggers a Large Transcriptional Response to Ca\[^{2+}\]/H\[^{1+}\] Burst—Among the genes showing differential transcription in response to amiodarone, many are also known to respond to elevation of cytosolic Ca\[^{2+}\]/H\[^{1+}\] (RCN1, ENAI–5, CMK1, CMK2, and GYP7), consistent with the drug-induced calcium burst reported previously (4, 5). Fig. 3A shows that a large percentage of the amiodarone responsive gene set was also induced (137 of 218 genes; 63%) or repressed (77 of 134 genes; 57%) upon exposure to 200 mM CaCl\(_2\) (10). A hierarchical clustering analysis confirmed that the transcriptional response to amiodarone most closely resembled the response to high CaCl\(_2\) (Fig. 4).

The transcription factor Crz1 is the major effector of calcineurin, a highly conserved Ca\[^{2+}\]/calmodulin-activated protein phosphatase that couples Ca\[^{2+}\] signals to downstream responses. Analogous to the NFAT family of transcription factors in mammalian cells, yeast Crz1 is dephosphorylated by calcineurin and migrates to the nucleus where it induces expression of target genes in response to a Ca\[^{2+}\] signal. We monitored the intracellular localization of Crz1-GFP upon exposure to amiodarone (15 \(\mu\)M) and high CaCl\(_2\) (50 mM). There was an immediate relocalization of Crz1 to the nucleus upon addition of amiodarone, similar to but more transient...
than the effect of 50 mM extracellular Ca\(^{2+}\) (Fig. 3, B and C). Combined with the microarray data, this result demonstrates that amiodarone-induced Ca\(^{2+}\) influx is capable of mounting a robust downstream transcriptional response.

**Amiodarone Induces a Stress Response**—Previous studies have identified a number of genes whose expression is altered under stress. In one study, expression of 216 genes was induced in response to seven stress conditions, namely heat, high salt, acid, alkali, \(\text{H}_2\text{O}_2\), hyperosmolarity, and diauxic shift (17). Of these, 54 gene transcripts (Fig. 3A and supplemental data Table 3S) were also induced by amiodarone, mostly as a response to Ca\(^{2+}\) stress; fewer (11 genes) were repressed in common with general stress response. Transcription of most (~60%) of these 54 genes is under the control of the MSN2/MSN4 stress-regulated factors. This indicates that the cell initiates its defense mechanism to cope with amiodarone toxicity.

**Amiodarone Induces a Unique Nutrient Starvation Response**—The majority of amiodarone-induced genes were involved in utilization of alternative carbon and nitrogen sources and mobilizing energy reserves (Table 1). This included genes for metabolizing the storage carbohydrates trehalose and glycogen (TPS2, GAC1, GLC3, GPH1, GSY1, GSY2, and others), fermenting non-glucose carbohydrates (FDH1, ACS1, ALD4, CYB2, and others), and metabolizing fatty acids (FOX2, POX1, POT1, ECI1, FAA2, CTA1, PXA1, PXA2, IDP3, TES1, and YPL156C). Concomitantly, we observed an induction of transporters for galactose (GAL2), maltose (MAL31), and high-affinity and moderate-affinity scavengers of glucose (HXT4, HXT5, and HXT6). Numerous genes involved in regulating glucose metabolism were up-regulated (MTH1, CAT8, REG2, NRG1, and MIG2) or repressed (STD1, CYR1, SRB8, MIG1, and GAL11) upon exposure to amiodarone. Similarly, genes under Nitrogen Catabolite Repression, including GAP1, MEP2, DAL80, DAL4, DAL7, PUT1, PUT4, UGA4, and PRB1, were derepressed. Induction of these genes is triggered by depletion of preferred nitrogen sources such as ammonium and glutamine. Collect-
Enrichment of functional categories for genes up-regulated by amiodarone

| Functional category                        | Frequency in amiodarone dataset | Genomic frequency | p value  |
|-------------------------------------------|---------------------------------|-------------------|----------|
| Metabolism (83)                           | 38.0                            | 24.6              | 5.66E-06 |
| C-compound & carbohydrate metabolism (44)| 20.1                            | 8.23              | 1.24E-08 |
| Fatty acid metabolism (6)                 | 2.75                            | 0.39              | 0.000148 |
| Energy (37)                               | 16.9                            | 5.98              | 4.56E-09 |
| Fermentation (non-glucose) (9)            | 4.12                            | 0.76              | 3.23E-05 |
| Energy reserve metabolism (9)             | 4.12                            | 0.91              | 0.000136 |
| Oxidation of fatty acids (5)              | 2.29                            | 0.14              | 6.09E-06 |
| Cellular transport (42)                   | 19.2                            | 16.9              | 0.197659 |
| Anion transport (5)                       | 2.29                            | 0.42              | 0.001937 |
| Sugar transport (6)                       | 2.75                            | 0.50              | 0.000659 |
| Amine/polyamine transport (3)             | 1.37                            | 0.22              | 0.012073 |
| Lipid/fatty acid transport (5)            | 2.29                            | 0.71              | 0.019083 |
| Drug/toxin transport (5)                  | 2.29                            | 0.63              | 0.011668 |
| Cell rescue, defense, and virulence (28)  | 12.8                            | 9.03              | 0.034936 |
| Oxidative stress response (5)             | 2.29                            | 0.89              | 0.047778 |
| pH stress response (2)                    | 0.91                            | 0.13              | 0.030590 |
| Heat shock response (3)                   | 1.37                            | 0.32              | 0.032343 |
| Catalase reaction (2)                     | 0.91                            | 0.03              | 0.001259 |

Enrichment of functional categories for genes down-regulated by amiodarone

| Functional category                        | Frequency in amiodarone dataset | Genomic frequency | p value  |
|-------------------------------------------|---------------------------------|-------------------|----------|
| Cell cycle and DNA processing (43)        | 33.5                            | 16.4              | 1.19E-07 |
| DNA synthesis and replication (8)         | 6.25                            | 2.25              | 0.007966 |
| Mitotic cell cycle and cell cycle control (29) | 22.6                        | 7.27              | 2.18E-08 |
| Cytokinesis/septum formation (6)          | 4.68                            | 1.15              | 0.003477 |
| Transcriptional control (17)              | 13.2                            | 8.07              | 0.027626 |
| Protein fate                             |                                 |                   |          |
| Modification by phosphorylation and dephosphorylation (9) | 7.03                       | 3.03              | 0.015387 |
| Small GTPase-mediated signal transduction (9) | 7.03                       | 0.93              | 2.55E-06 |
| Cell type differentiation (24)            | 18.7                            | 7.37              | 1.60E-05 |
| Budding, cell polarity, and filament formation (17) | 13.2                       | 5.1               | 0.000245 |
| Metabolism                              |                                 |                   |          |
| Regulation of C-compound and carbohydrate metabolism (7) | 6.46                       | 2.07              | 0.001654 |

Transcriptional Profiling of Amiodarone Response in Yeast

Amiodarone activates a starvation response by a mechanism independent of Ca2+ signaling. The pattern of global transcriptional change induced by amiodarone is reminiscent of a starvation response. Indeed, hierarchical clustering analysis demonstrated that the transcriptional response within 10 min of exposure to amiodarone was similar to glucose and nitrogen starvation observed during stationary phase, rapamycin treatment, and late stages of diauxic shift and nitrogen depletion (Fig. 4A). Thus, the rapid and extensive re-programming of yeast metabolic networks to adapt to nutrient-limiting conditions, despite the availability of glucose and ammonium in the medium, suggests that amiodarone may disrupt nutrient sensing and regulatory circuitry.

Comparison of the transcriptional profiles in response to amiodarone and CaCl2 by K-means clustering revealed a signature response of amiodarone; a cluster of 52 genes was induced at least 2-fold by amiodarone but not by CaCl2 (Fig. 4B). Of these, 25 genes are known to be activated upon exposure to 200 mM CaCl2: high levels of Ca2+ activate a starvation response within 15 min of exposure to amiodarone (15). Notably, none of the glucose metabolism regulators listed above, with the exception of GLK1, was induced by amiodarone (15).

Among the 25 genes induced by amiodarone, the calcium-responsive genes were repressed by high Ca2+ (promoting DNA replication), FKH2 (promoting G2/M transition), and SWI5 and ACE2 (promoting M/G1 transition). In addition, genes involved in the processes of DNA synthesis and replication, and cytokinesis were repressed. Other important cell cycle regulators, including CLB3, CLB4, and CLB5, were also repressed, albeit at lower levels (1.5–2-fold). To investigate this large scale repression of cell cycle genes was mediated by Ca2+, we examined the DNA microarray dataset previously reported for calcium response (10). This dataset includes genes repressed by Ca2+ (200 mM) that have not been analyzed, to date. Among the 712 genes repressed by Ca2+ within 15 min, 114 genes are in the functional category of cell cycle and DNA processing. Of the 43 cell cycle genes repressed by amiodarone, 26 were also repressed by high Ca2+, including all key cell cycle regulators listed above, with the exception of CLB3 and CLB4. Therefore, Ca2+ signaling plays a prominent role in mediating repression of the cell cycle genes by amiodarone.

Genes repressed by amiodarone are required to promote progression through all phases of the cell cycle, suggesting that the drug might impose a delay at multiple stages of the cell cycle. To examine this hypothesis, we assessed the effect of amiodarone in synchronous cultures. In an asynchronous early log phase control culture, the cell populations in G1, S, and G2/M phases were 16, 22, and 60%, respectively. Following treatment with 15 mM amiodarone for 0.5 h, cell populations in G1, S, and G2/M phases were 20, 0, and 80%, respectively. In addition, populations of cells with lower DNA content appeared indicative of cell death and DNA degradation. Eight hours after amiodarone treatment, the cell cycle profile returned to normal (Fig. 5A). These results suggested that the transitions from G1 to S phase and from G2/M to G1 were temporarily blocked. To further assess the blockage of cell cycle at specific stages, we examined the effect of amiodarone in synchronous cultures. Wild type yeast were arrested in S phase with hydroxyurea and released to YPD. Amiodarone was added...
FIGURE 5. Amiodarone delays cell cycle progression. Total DNA content was assessed by flow cytometry analysis and presented as cell counts (y axis) versus DNA content (x axis; arrows indicate 1C and 2C). A, early log phase culture (OD 0.1) of the wild type (BY4742) was treated with amiodarone (15 μM) for 8 h. 0 time point is the sample before addition of amiodarone. B, early log phase culture of the wild type (BY4742) was synchronized at S phase by 0.2 M hydroxyurea for 1 h and then released to YPD for 15 min for recovery. A sample was collected and analyzed as the 0 time point. The remaining culture was split into two parts. One part was treated with Me2SO, whereas the other with amiodarone (15 μM). C, the culture was synchronized as above and then released to YPD for 60 min for the cells to pass through S phase. A sample was collected and analyzed as the 0 time point. The remaining culture was treated with Me2SO or amiodarone as in B.

FIGURE 6. Swe1 is involved in mediating G2/M delay caused by amiodarone. A, early log phase (OD 0.1) culture of the swe1Δ strain was synchronized at S phase by 0.2 M hydroxyurea for 1 h and then released to YPD for 60 min for the cells to pass through S phase. Samples were treated as described in the legend to Fig. 5. B, percentage of multinucleate cells in wild type (WT) and swe1Δ cultures treated with amiodarone (15 μM). Samples at 0 time point were collected before adding amiodarone. Nuclei were stained with 4',6-diamidino-2-phenylindole (1 μg/ml) and 100–400 cells were counted to calculate percentage.

to the culture during transition from S to G2/M phase (Fig. 5B) or from G2/M to G1 phase (Fig. 5C). These analyses showed that the transition from S to G2/M phase was temporarily delayed, whereas the transition from G2/M to G1 phase was significantly blocked in the presence of drug.

Elevation of Swe1 kinase activity is required for transient G2/M arrest, by phosphorylation and inhibition of Cdc28, under several conditions including exposure to calcium (in a zds1Δ mutant), endoplasmic reticulum stress, and hyperosmotic stress (18–20). To investigate the role of Swe1 in amiodarone-induced G2/M arrest, we examined cell cycle progression in a swe1Δ mutant following synchronization with hydroxyurea treatment and release. In contrast to wild type, swe1Δ cells failed to arrest in G2/M phase when treated with 15 μM amiodarone (Fig. 6A). Consistent with this, 0.5 h after amiodarone treatment, asynchronous swe1Δ mutant culture contained ~10% multinucleate cells, whereas the wild-type culture contained ~2% of multinucleate cells (Fig. 6B). Taken together, these results confirmed the role of Swe1 in mediating G2/M arrest and indicated a specific involvement in blocking nuclear division.

Calcineurin Is Critical for Viability in Amiodarone and Mediates G2/M Block—Deletion of calcineurin (cnb1Δ) or inhibition by FK506 was previously demonstrated to confer growth hypersensitivity to amiodarone (5). We show that acute inhibition of calcineurin with FK506 increased cell death in amiodarone, as evidenced by accumulation of cells with decreased DNA content (Fig. 7A). Furthermore, synchronized cnb1Δ cells progressed from G2/M phase to G1 phase in a manner similar to untreated cells, albeit with the appearance of sub-G2/M peaks of cells, likely representing DNA breakdown (Fig. 7B). In the absence of amiodarone, neither FK506 nor disruption of CNB1 had a discernable effect on cell death or cell cycle. Together, these data indicated that calcineurin was involved in mediating the G2/M arrest induced by amiodarone and that in the absence of cell cycle arrest, increased cell death ensued.

DISCUSSION

Mechanistic Insights from Transcriptional Profiling—Amiodarone is a cationic amphiphilic drug that has a strong preference to partition into the membrane bilayer where it has been shown to exert an ordering effect on lipids, resulting in a decrease in membrane fluidity (2, 21). In yeast, amiodarone triggers the rapid opening of plasma membrane calcium channels (4, 5). Both the kinetics and amplitude of the Ca2+ burst are dose-dependent and correlate directly with drug toxicity.3 Yeast mutants defective in Ca2+ homeostasis are hypersensitive to the drug (5, 7). These observations led to a model in

3 S. Muend and R. Rao, unpublished observations.
Transcriptional Profiling of Amiodarone Response in Yeast

which the antifungal effects of amiodarone are a consequence of Ca\(^{2+}\) stress. The results from transcriptional profiling directly support this model: over half of the genes differentially transcribed in response to amiodarone were previously identified in a microarray analysis of the response to high Ca\(^{2+}\) (10). Similar to the effect of 50 mM extracellular CaCl\(_2\), we showed that amiodarone (15 \(\mu\)M) elicited the rapid relocalization of the calcineurin-responsive transcription factor Crz1 to the nucleus. We conclude that Ca\(^{2+}\) is a major effector in mediating amiodarone cytotoxicity.

Several lines of evidence indicate that amiodarone also elicits a unique starvation response. First, up-regulated transcripts were enriched in categories of energy and metabolism, the two major functional categories also induced in a genome wide study of glucose limitation (22). Second, amiodarone triggered the derepression of the genes for utilization of alternative carbon sources that would normally be under carbon catabolite repression in the presence of glucose (23–26). Consistent with a major metabolic reorganization, numerous regulatory genes in glucose signaling pathways were differentially transcribed in response to amiodarone. Third, the induction of genes for hexose transporters with moderate to high affinity recapitulated the orderly increase in gene transcript levels for hexose transporters of increasing affinity as the cells attempt to scavenge the remaining glucose during the course of diauxic shift (27). Finally, the increased transcription of genes under nitrogen catabolite repression is normally a response to the depletion of preferred nitrogen sources (ammonium and glutamine) in the growth medium (28–30). Thus, the prominent transcriptional adaptation to starvation that occurs within minutes of drug addition despite a sufficient supply of glucose and ammonium suggests that amiodarone disrupts nutrient sensing or regulatory networks. A unique set of genes, induced by amiodarone but not by CaCl\(_2\), constitutes a signature amiodarone response (Fig. 4B). This includes the genes for glucose metabolism regulation, alternative carbon source utilization, and glucose scavengers. Additionally, several glucose regulators repressed by amiodarone were not repressed by CaCl\(_2\). Therefore, amiodarone elicits the starvation response by a mechanism independent of Ca\(^{2+}\). Further investigation is required to determine whether activation of the starvation response involves specific signaling pathways, such as cAMP/protein kinase A and AMPK (AMP-activated protein kinase).

In addition to a fungicidal effect, we found that amiodarone also elicited a dose-dependent prolongation of doubling time. Consistent with this, a broad spectrum of cell cycle genes was repressed and flow cytometry analysis confirmed the drug-induced delay in cell cycle progression at G\(_1\), S, and G\(_2\)/M phases. Exposure to Ca\(^{2+}\) has been reported to arrest cells at G\(_2\) phase in a zds\(_1\) mutant background, although in wild type cells, the effect of high calcium on cell cycle is minimal (18). Our examination of the global transcriptional change upon exposure to 200 mM CaCl\(_2\) revealed repression of a large number of cell

Gene expression data for CaCl\(_2\) (10) and antifungals (14) were previously published: exposure to CaCl\(_2\) (5, 15 and 30 min), caspofungin (\(\sim 3\) h), amphotericin B (\(\sim 3\) h), 5-fluorocytosine (\(\sim 3\) h), and ketoconazole (\(\sim 3\) h). The clustering method is the same as that described in the legend to Fig. 4A.

FIGURE 8. Transcriptional response to amiodarone is distinct from those to other antifungals. Hierarchical clustering of 1977 genes that were differentially regulated by at least 2-fold in one or more of the six conditions shown.
Transcriptional Profiling of Amiodarone Response in Yeast

...modulates genes involved in lipid biosynthesis and sterol uptake, whereas caspofungin inhibits β-1,3-glucan synthase and triggers the induction of the cell wall integrity pathway. The pore forming compound amphotericin B induces genes for membrane reconstruction, cell stress, cell wall integrity, and phosphate uptake and 5-fluorocytosine elicits expression change for genes involved in DNA synthesis, protein synthesis, and DNA damage response.

Our results highlight the pathway of amiodarone and Ca\(^{2+}\)-stress-mediated cell death as a promising target for antifungal development. Indeed, calcineurin inhibitors have already been shown to act synergistically with azoles and other antifungals (34, 35), consistent with our report on the synergy between amiodarone and azoles. In light of this, screening amiodarone derivatives in conjunction with existing drugs provides a promising strategy in the battle against fungal pathogens.

Acknowledgments—We thank Dr. Ameeta Agarwal for providing formatted gene lists for analysis and Dr. Martha Cyert for GFP-Crz1.

REFERENCES

1. Courchesne, W. E. (2002) J. Pharmacol. Exp. Ther. 300, 195–199
2. Rosa, S. M., Antunes-Madeira, M. C., Matos, M. J., Jurado, A. S., and Madeira, V. M. (2000) Biochim. Biophys. Acta 1487, 286–295
3. Benaim, G., Sanders, J. M., Garcia-Marchan, Y., Colina, C., Lira, R., Caldera, A. R., Payares, G., Sanoa, C., Burgos, J. M., Leon-Rossell, A., Concepcion, J. L., Schijman, A. G., Levin, M., Oldfield, E., and Urbina, J. A. (2006) J. Med. Chem. 49, 892–899
4. Courchesne, W. E., and Ozturk, S. (2003) Mol. Microbiol. 47, 223–234
5. Gupta, S. S., Ton, V. K., Beaudrey, V., Rulli, S., Cunningham, K., and Rao, R. (2003) J. Biol. Chem. 278, 28831–28839
6. Poznikovskiy, A. L., Knorre, D. A., Markova, O. V., Hyman, A. A., Skulachev, V. P., and Severin, F. F. (2005) J. Cell Biol. 168, 257–269
7. Yadav, J., Muend, S., Zhang, Y., and Rao, R. (2007) Mol. Biol. Cell 18, 1480–1489
8. Schnitt, M. E., Brown, T. A., and Trumpower, B. L. (1990) Nucleic Acids Res. 18, 3091–3092
9. de Hoon, M. J., Imoto, S., Nolan, J., and Miyano, S. (2004) Bioinformatics 20, 1453–1454
10. Yoshimoto, H., Salsman, K., Gasch, A. P., Li, H. X., Ogawa, N., Botstein, D., Brown, P. O., and Cyert, M. S. (2002) J. Biol. Chem. 277, 31079–31088
11. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and Schreiber, S. L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14866–14870
12. Gasch, A. P., Spellman, P. T., Kao, C. M., Carmel-Harel, O., Eisen, M. B., Storz, G., Botstein, D., and Brown, P. O. (2000) Mol. Cell Biol. 11, 4241–4257
13. DeRisi, J. L., Iyer, V. R., and Brown, P. O. (1997) Science 278, 680–686
14. Agarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., and Clark, A. M. (2003) J. Biol. Chem. 278, 34998–35015
15. Kafadar, K. A., and Cyert, M. S. (2004) Eukaryot. Cell 3, 1147–1153
16. Millard, P. J., Roth, B. L., Thi, H. P., Yue, S. T., and Haugland, R. P. (1997) Appl. Environ. Microbiol. 63, 2897–2905
17. Causton, H. C., Ren, B., Koh, S. S., Harbison, C. T., Kanin, E., Jennings, E. G., Lee, T. I., True, H. L., Lander, E. S., and Young, R. A. (2001) Mol. Cell 20, 323–337
18. Mizumura, M., Hirata, D., Miyahara, K., Tsuchiya, E., and Miyakawa, T. (1998) Nature 392, 303–306
19. Alexander, M. R., Tyers, M., Perret, M., Craig, B. M., Fang, K. S., and Gustin, M. C. (2001) Mol. Biol. Cell 12, 53–62
20. Bonilla, M., and Cunningham, K. W. (2003) Mol. Biol. Cell 14, 4296–4305
21. Antunes-Madeira, M. C., Videira, R. A., Kluppel, M. L., and Madeira, V. V. (1995) Int. J. Cardiol. 48, 211–218
22. Wu, J., Zhang, N., Hayes, A., Panoutsopoulou, K., and Oliver, S. G. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 3148–3153
23. Schuller, H. J. (2003) Curr. Genet. 43, 139–160
24. Boer, V. M., de Winde, J. H., Pronk, J. T., and Piper, M. D. (2003) J. Biol. Chem. 278, 3265–3274
25. Rolland, F., Winderickx, J., and Thevelein, J. M. (2002) FEMS Yeast Res. 2, 183–201
26. Santangelo, G. M. (2006) Microbiol. Mol. Biol. Rev. 70, 253–282
27. Brauer, M. J., Salaganha, A. J., Dolinski, K., and Botstein, D. (2005) Mol. Biol. Cell 16, 2503–2517
28. Magasanik, B., and Kaiser, C. A. (2002) Gene (Amst.) 290, 1–18
29. Marzluf, G. A. (1997) Microbiol. Mol. Biol. Rev. 61, 17–32
30. Cooper, T. G. (2002) FEMS Microbiol. Rev. 26, 223–238
31. Birrell, G. W., Brown, J. A., Wu, H. L., Giaever, G., Chu, A. M., Davis, R. W., and Brown, J. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 8778–8783
32. Begley, T. J., Rosenbach, A. S., Ideker, T., and Samson, L. D. (2002) Mol. Cancer Res. 1, 103–112
33. Haugen, A. C., Kelley, R., Collins, J. B., Tucker, C. J., Deng, C., Afshari, C. A., Brown, J. M., Ideker, T., and Van Houten, B. (2004) Genome Biol. 5, R95
34. Onyewu, C., Eads, E., Schell, W. A., Perfect, J. R., Ullmann, Y., Kaufman, G., Horwitz, B. A., Berdicevsky, I., and Heitman, J. (2007) Antimicrob Agents Chemother. 10, 3743–3746
35. Steinbach, W. J., Reedy, J. L., Cramer, R. A., Jr., Perfect, J. R., and Heitman, J. (2007) Nat. Rev. Microbiol. 5, 418–430
36. Saldana, A. J. (2004) Bioinformatics 20, 3246–3248